Bicara Therapeutics Inc. Common Stock
BCAXBicara Therapeutics Inc. (BCAX) is a biotechnology company focused on developing innovative immuno-oncology therapies. The company specializes in creating targeted treatments that modulate the immune system to combat cancer, leveraging its proprietary platform to develop novel antibody-based therapies.
$17.95 +1.73 (10.45%)
Company News
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
Bicara Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference, highlighting its lead program ficerafusp alfa, a bifunctional antibody designed to treat solid tumor cancers by targeting EGFR and TGF-β.
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Oncology drug delivery is advancing through nanomedicine technologies, with companies developing innovative platforms to improve drug bioavailability, reduce toxicity, and enhance therapeutic effectiveness in cancer treatments.
